Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 100$ stock price

<< Previous

Bullboard Posts

Next >>

Comment by Marky1on Feb 15, 2021 12:57pm

143 Views

Post# 32568613

RE:RE:RE:RE:100$ stock price

So, if I plug in your 60,000,000 shares at a MarketCap of 5B$ CDN.....I now get 85$ ,....I'm thinking maybe Dr. Haut may negotiate at a higher price than 4B$ usd....much much more
iMHO

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features